Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Insulin aspart + dextrose is a combination of two substances: insulin aspart, a rapid-acting recombinant human insulin analog used to lower blood glucose by mimicking the body's natural insulin response, and dextrose, a form of glucose commonly used in clinical settings as a source of immediate energy or to treat hypoglycemia. Insulin aspart promotes glucose uptake into muscle and adipose tissue, suppresses hepatic glucose production, and inhibits lipolysis and proteolysis, acting mainly through the insulin receptor tyrosine kinase on target tissues[1][2]. Dextrose increases circulating blood glucose via direct carbohydrate supplementation. Such a combination may occasionally be employed in controlled clinical/research settings (e.g., glucose clamp studies) but is not a standard, marketed combination therapy or product.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on insulin aspart + dextrose.